BUY Biocon Ltd — Axis Securities
byAxis SecuritiesHorizon: NA (inferred 1 year)13 Nov 2025via Institutional / Brokerage Research
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Long-term trend bullish — 200-day average rising over the past quarter
Technicals · trend·23 Oct · 2d ago
Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates
NewsCnbc-Tv18·14 Oct · 2w ago
5 other SEBI-registered advisors have active long-term BUY calls on this stock
Advisor consensus · same horizon·7 Aug · 3mo ago
Nothing found in this tip’s window yet.
1 advisor has an active short-term SELL call on this stock
Advisor consensus · adjacent horizon·9 Oct · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Biocon
- BUY — Kunal Bothra22 Oct 2026 · ~2 weeks · target ₹345 · SL hit
- SELL — Rajesh Satpute9 Oct 2026 · ~3 months · target ₹335 · Active
- BUY — Axis Securities19 Sept 2026 · ~3 months · target ₹424 · Active
- BUY — Prakash Gaba17 Sept 2026 · ~2 weeks · target ₹390 · Target hit
- BUY — Vikas Salunkhe, Nirmal Bang Securities27 Aug 2026 · ~2 weeks · target ₹440 · SL hit
More from Axis Securities
- BUY Eternal22 Oct 2026 · ~1 year · target ₹390 · Active
- BUY CREDITACCESS GRAMEEN22 Oct 2026 · ~1 year · target ₹1,405 · Active
- BUY CCL Products (India)19 Oct 2026 · ~1 year · target ₹1,255 · Active
- BUY Federal Bank19 Oct 2026 · ~1 year · target ₹405 · Active
- BUY LTM19 Oct 2026 · ~1 year · target ₹4,960 · Active

